Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Quoin Pharmaceuticals, Ltd. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
QNRX
Nasdaq
2830
quoinpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
- Jun 26th, 2025 6:30 am
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
- Jun 24th, 2025 6:30 am
QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further
- May 28th, 2025 7:13 am
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study
- May 22nd, 2025 6:07 am
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
- May 22nd, 2025 5:30 am
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
- May 20th, 2025 5:30 am
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
- May 14th, 2025 5:30 am
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
- May 13th, 2025 6:00 am
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
- May 6th, 2025 6:00 am
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
- Apr 30th, 2025 5:30 am
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
- Apr 10th, 2025 5:30 am
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
- Apr 2nd, 2025 5:30 am
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
- Mar 25th, 2025 5:30 am
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
- Mar 17th, 2025 8:10 am
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
- Mar 13th, 2025 5:30 am
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
- Mar 6th, 2025 6:00 am
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease
- Mar 5th, 2025 8:16 am
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
- Mar 4th, 2025 5:30 am
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
- Feb 27th, 2025 5:30 am
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
- Feb 25th, 2025 5:30 am
Scroll